Daniel Batlle

List of Publications by Year
in descending order

128	8,991	47	92
papers	citations	h-index	g-index
		47006	42399

131	131	131	10348
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Serum potassium changes during hypothermia and rewarming: a case series and hypothesis on the mechanism. CKJ: Clinical Kidney Journal, 2023, 16, 827-834.	2.9	1
2	Tribute to Lewis Landsberg: A Giant of Academic Medicine. Hypertension, 2022, 79, 291-292.	2.7	0
3	Circulating ACE2-expressing extracellular vesicles block broad strains of SARS-CoV-2. Nature Communications, 2022, 13, 405.	12.8	92
4	Potential SARS-CoV-2 kidney infection and paths to injury. Nature Reviews Nephrology, 2022, 18, 275-276.	9.6	6
5	A Novel Soluble ACE2 Protein Provides Lung and Kidney Protection in Mice Susceptible to Lethal SARS-CoV-2 Infection. Journal of the American Society of Nephrology: JASN, 2022, 33, 1293-1307.	6.1	26
6	Spherical nucleic acids as an infectious disease vaccine platform. Proceedings of the National Academy of Sciences of the United States of America, 2022, 119, e2119093119.	7.1	20
7	Effect of Sodium Zirconium Cyclosilicate on Serum Potassium and Bicarbonate in Patients with Hyperkalemia and Metabolic Acidosis Associated with Chronic Kidney Disease: Rationale and Design of the NEUTRALIZE Study. Nephron, 2022, 146, 599-609.	1.8	5
8	Evidence in favor of the essentiality of human cell membrane-bound ACE2 and against soluble ACE2 for SARS-CoV-2 infectivity. Cell, 2022, 185, 1837-1839.	28.9	17
9	Kidney Angiotensin in Cardiovascular Disease: Formation and Drug Targeting. Pharmacological Reviews, 2022, 74, 462-505.	16.0	18
10	An update on ACE2 amplification and its therapeutic potential. Acta Physiologica, 2021, 231, e13513.	3.8	33
11	Knockout of aminopeptidase A in mice causes functional alterations and morphological glomerular basement membrane changes in the kidneys. Kidney International, 2021, 99, 900-913.	5.2	2
12	A Novel Soluble ACE2 Variant with Prolonged Duration of Action Neutralizes SARS-CoV-2 Infection in Human Kidney Organoids. Journal of the American Society of Nephrology: JASN, 2021, 32, 795-803.	6.1	82
13	COVID-19 and its impact on the kidney and the nephrology community. CKJ: Clinical Kidney Journal, 2021, 14, i1-i5.	2.9	1
14	Evidence For and Against Direct Kidney Infection by SARS-CoV-2 in Patients with COVID-19. Clinical Journal of the American Society of Nephrology: CJASN, 2021, 16, 1755-1765.	4.5	54
15	Revisiting the renin-angiotensin system. Molecular and Cellular Endocrinology, 2021, 529, 111268.	3.2	3
16	Emerging importance of ACE2 in external stratified epithelial tissues. Molecular and Cellular Endocrinology, 2021, 529, 111260.	3.2	6
17	CONNed in Pregnancy. Hypertension, 2021, 78, 241-249.	2.7	2
18	Ang II (Angiotensin II) Conversion to Angiotensin-(1-7) in the Circulation Is POP (Prolyloligopeptidase)-Dependent and ACE2 (Angiotensin-Converting Enzyme 2)-Independent. Hypertension, 2020, 75, 173-182.	2.7	155

#	Article	IF	Citations
19	Severe Acute Respiratory Syndrome Coronavirus 2, COVID-19, and the Renin-Angiotensin System. Hypertension, 2020, 76, 1350-1367.	2.7	46
20	Kidney and Lung ACE2 Expression after an ACE Inhibitor or an Ang II Receptor Blocker: Implications for COVID-19. Journal of the American Society of Nephrology: JASN, 2020, 31, 1941-1943.	6.1	95
21	Cuffless Blood Pressure Monitoring. Clinical Journal of the American Society of Nephrology: CJASN, 2020, 15, 1531-1538.	4.5	56
22	The ACE2â€deficient mouse: A model for a cytokine stormâ€driven inflammation. FASEB Journal, 2020, 34, 10505-10515.	0.5	41
23	Interaction of SARS-CoV-2 and Other Coronavirus With ACE (Angiotensin-Converting Enzyme)-2 as Their Main Receptor. Hypertension, 2020, 76, 1339-1349.	2.7	147
24	Rigor before speculation in COVID-19 therapy. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2020, 318, L1027-L1028.	2.9	3
25	Acute Kidney Injury in COVID-19: Emerging Evidence of a Distinct Pathophysiology. Journal of the American Society of Nephrology: JASN, 2020, 31, 1380-1383.	6.1	453
26	Renin-Angiotensin System Blockers and the COVID-19 Pandemic. Hypertension, 2020, 75, 1382-1385.	2.7	412
27	Cyclophilins A and B oppositely regulate renal tubular epithelial cell phenotype. Journal of Molecular Cell Biology, 2020, 12, 499-514.	3.3	12
28	Authorsâ€™ Reply. Journal of the American Society of Nephrology: JASN, 2020, 31, 1918-1919.	6.1	0
29	Sound Science before Quick Judgement Regarding RAS Blockade in COVID-19. Clinical Journal of the American Society of Nephrology: CJASN, 2020, 15, 714-716.	4.5	74
30	Soluble angiotensin-converting enzyme 2: a potential approach for coronavirus infection therapy?. Clinical Science, 2020, 134, 543-545.	4.3	369
31	ACE2, the kidney and the emergence of COVID-19 two decades after ACE2 discovery. Clinical Science, 2020, 134, 2791-2805.	4.3	14
32	Progressive Hypertension and Severe Left Ventricular Outflow Tract Obstruction. Hypertension, 2019, 74, 1216-1225.	2.7	2
33	SuO007CYCLOPHILINS A AND B OPPOSITELY REGULATE RENAL TUBULAR EPITHELIAL CELL PHENOTYPE. Nephrology Dialysis Transplantation, 2019, 34, .	0.7	0
34	Urinary angiotensinogen antedates the development of stage 3 CKD in patients with type 1 diabetes mellitus. Physiological Reports, 2019, 7, e14242.	1.7	10
35	Angiotensin-(1-7) for diabetic kidney disease: better than an angiotensin-converting enzyme inhibitor alone?. Kidney International, 2019, 96, 815-817.	5.2	9
36	Urinary Renin in Patients and Mice With Diabetic Kidney Disease. Hypertension, 2019, 74, 83-94.	2.7	33

#	Article	IF	Citations
37	Novel Variants of Angiotensin Converting Enzyme-2 of Shorter Molecular Size to Target the Kidney Renin Angiotensin System. Biomolecules, 2019, 9, 886.	4.0	39
38	Proximal renal tubular acidosis with and without Fanconi syndrome. Kidney Research and Clinical Practice, 2019, 38, 267-281.	2.2	30
39	Single-cell RNA profiling of glomerular cells in diabetic kidney: a step forward for understanding diabetic nephropathy. Annals of Translational Medicine, 2019, 7, S340-S340.	1.7	5
40	The Urine Anion Gap in Context. Clinical Journal of the American Society of Nephrology: CJASN, 2018, 13, 195-197.	4.5	25
41	Novel ACE2-Fc chimeric fusion provides long-lasting hypertension control and organ protection in mouse models of systemic renin angiotensin system activation. Kidney International, 2018, 94, 114-125.	5.2	94
42	Apelinergic system in the kidney: implications for diabetic kidney disease. Physiological Reports, 2018, 6, e13939.	1.7	13
43	Biological Variability of Estimated GFR and Albuminuria in CKD. American Journal of Kidney Diseases, 2018, 72, 538-546.	1.9	62
44	Renal Tubular Acidosis and the Nephrology Teaching Paradigm. Advances in Chronic Kidney Disease, 2018, 25, 301-302.	1.4	0
45	Hypokalemic Distal Renal Tubular Acidosis. Advances in Chronic Kidney Disease, 2018, 25, 303-320.	1.4	43
46	Hyperkalemic Forms of Renal Tubular Acidosis: Clinical and Pathophysiological Aspects. Advances in Chronic Kidney Disease, 2018, 25, 321-333.	1.4	25
47	Prolylcarboxypeptidase deficiency is associated with increased blood pressure, glomerular lesions, and cardiac dysfunction independent of altered circulating and cardiac angiotensin II. Journal of Molecular Medicine, 2017, 95, 473-486.	3.9	40
48	Urine RAS components in mice and people with type 1 diabetes and chronic kidney disease. American Journal of Physiology - Renal Physiology, 2017, 313, F487-F494.	2.7	32
49	Metabolic Acidosis or Respiratory Alkalosis? Evaluation of a Low Plasma Bicarbonate Using the Urine Anion Gap. American Journal of Kidney Diseases, 2017, 70, 440-444.	1.9	16
50	A Fluorometric Method of Measuring Carboxypeptidase Activities for Angiotensin II and Apelin-13. Scientific Reports, 2017, 7, 45473.	3.3	17
51	Angiotensin-converting enzyme 2 amplification limitedÂto the circulation does not protect miceÂfromÂdevelopment of diabetic nephropathy. Kidney International, 2017, 91, 1336-1346.	5.2	49
52	Angiotensinogen as a biomarker of acute kidney injury. CKJ: Clinical Kidney Journal, 2017, 10, 759-768.	2.9	37
53	The Use of Bedside Urinary Parameters in the Evaluation of Metabolic Acidosis. , 2016, , 39-51.		1
54	Urinary Angiotensinogen: A Promising Biomarker of AKI Progression in Acute Decompensated Heart Failure: What Does It Mean?. Clinical Journal of the American Society of Nephrology: CJASN, 2016, 11, 1515-1517.	4.5	11

#	Article	IF	Citations
55	Snapshot Hemodynamics and Clinical Outcomes in Hypertension. Hypertension, 2016, 67, 270-271.	2.7	12
56	The Colon as the Potassium Target: Entering the Colonic Age of Hyperkalemia Treatment?. EBioMedicine, 2015, 2, 1562-1563.	6.1	12
57	Plasma and Kidney Angiotensin Peptides: Importance of the Aminopeptidase A/Angiotensin III Axis. American Journal of Hypertension, 2015, 28, 1418-1426.	2.0	28
58	Angiotensins and the Heart. Hypertension, 2015, 66, 260-262.	2.7	7
59	Cross-Disciplinary Biomarkers Research. Clinical Journal of the American Society of Nephrology: CJASN, 2015, 10, 894-902.	4.5	24
60	ACE2 deficiency increases NADPH-mediated oxidative stress in the kidney. Physiological Reports, 2014, 2, e00264.	1.7	58
61	Angiotensin-Converting Enzyme 2â€“Independent Action of Presumed Angiotensin-Converting Enzyme 2 Activators. Hypertension, 2014, 63, 774-782.	2.7	101
62	Effect of Insulin on ACE2 Activity and Kidney Function in the Non-Obese Diabetic Mouse. PLoS ONE, 2014, 9, e84683.	2.5	45
63	ACE2 alterations in kidney disease. Nephrology Dialysis Transplantation, 2013, 28, 2687-2697.	0.7	105
64	Physiologic Principles in the Clinical Evaluation of Electrolyte, Water, and Acidâ€“Base Disorders. , 2013, , 2477-2511.		1
65	Reduced plasma ACE2 activity in dialysis patients: another piece in the conundrum of factors involved in hypertension and cardiovascular morbidity?. Nephrology Dialysis Transplantation, 2013, 28, 2200-2202.	0.7	14
66	Regulation of urinary ACE2 in diabetic mice. American Journal of Physiology - Renal Physiology, 2013, 305, F600-F611.	2.7	60
67	Predominance of AT1 Blockade Over Masâ€“Mediated Angiotensin-(1â€“7) Mechanisms in the Regulation of Blood Pressure and Reninâ€“Angiotensin System in mRen2.Lewis Rats. American Journal of Hypertension, 2013, 26, 583-590.	2.0	29
68	Proximal renal tubular acidosis: a not so rare disorder of multiple etiologies. Nephrology Dialysis Transplantation, 2012, 27, 4273-4287.	0.7	131
69	Genetic causes and mechanisms of distal renal tubular acidosis. Nephrology Dialysis Transplantation, 2012, 27, 3691-3704.	0.7	163
70	Podocyte-specific overexpression of human angiotensin-converting enzyme 2 attenuates diabetic nephropathy in mice. Kidney International, 2012, 82, 292-303.	5.2	98
71	Murine Recombinant Angiotensin-Converting Enzyme 2. Hypertension, 2012, 60, 730-740.	2.7	89
72	Angiotensin-converting enzyme 2: enhancing the degradation of angiotensin II as a potential therapy for diabetic nephropathy. Kidney International, 2012, 81, 520-528.	5.2	105

#	Article	IF	Citations
73	Evaluation of Renal Hypoxia in Diabetic Mice by BOLD MRI. Investigative Radiology, 2010, 45, 819-822.	6.2	59
74	Vascular Angiotensin-Converting Enzyme 2. Circulation Research, 2010, 107, 822-824.	4.5	5
75	Targeting the Degradation of Angiotensin II With Recombinant Angiotensin-Converting Enzyme 2. Hypertension, 2010, 55, 90-98.	2.7	273
76	Potential benefits of alkali therapy to prevent GFR loss: time for a palatable â€˜solutionâ€™ for the management of CKD. Kidney International, 2010, 78, 1065-1067.	5.2	13
77	ACE2 and Diabetes: ACE of ACEs?. Diabetes, 2010, 59, 2994-2996.	0.6	95
78	Apelin and ACE2 in cardiovascular disease. Current Opinion in Investigational Drugs, 2010, 11, 273-82.	2.3	49
79	Localization of ACE2 in the renal vasculature: amplification by angiotensin II type 1 receptor blockade using telmisartan. American Journal of Physiology - Renal Physiology, 2009, 296, F398-F405.	2.7	188
80	Angiotensin-converting enzyme 2: Possible role in hypertension and kidney disease. Current Hypertension Reports, 2008, 10, 70-77.	3.5	17
81	Pharmacologic modulation of ACE2 expression. Current Hypertension Reports, 2008, 10, 410-4.	3.5	69
82	Angiotensinâ€converting enzyme 2 and the kidney. Experimental Physiology, 2008, 93, 549-556.	2.0	38
83	Physiologic Principles in the Clinical Evaluation of Electrolyte, Water, and Acid-Base Disorders. , 2008, , 2113-2141.		1
84	Effect of calcium-sensing receptor activation in models of autosomal recessive or dominant polycystic kidney disease. Nephrology Dialysis Transplantation, 2008, 24, 526-534.	0.7	45
85	Acute Renal Failure from Adulteration of Milk with Melamine. Scientific World Journal, The, 2008, 8, 974-975.	2.1	24
86	New aspects of the reninâ€“angiotensin system: angiotensin-converting enzyme 2 â€“ a potential target for treatment of hypertension and diabetic nephropathy. Current Opinion in Nephrology and Hypertension, 2008, 17, 250-257.	2.0	30
87	High CO2 Levels Impair Alveolar Epithelial Function Independently of pH. PLoS ONE, 2007, 2, e1238.	2.5	108
88	Kidney Vacuolar H+-ATPase: Physiology and Regulation. Seminars in Nephrology, 2006, 26, 361-374.	1.6	19
89	Acid-Base and Potassium Disorders in Liver Disease. Seminars in Nephrology, 2006, 26, 466-470.	1.6	46
90	Distal Renal Tubular Acidosis and the Potassium Enigma. Seminars in Nephrology, 2006, 26, 471-478.	1.6	52

#	Article	IF	Citations
91	Carlos Margarit-In Memoriam, 1950-2005. Scientific World Journal, The, 2006, 6, 318-352.	2.1	0
92	Paricalcitol Capsule for the Treatment of Secondary Hyperparathyroidism in Stages 3 and 4 CKD. American Journal of Kidney Diseases, 2006, 47, 263-276.	1.9	198
93	ACE and ACE2 Activity in Diabetic Mice. Diabetes, 2006, 55, 2132-2139.	0.6	270
94	Glomerular Localization and Expression of Angiotensin-Converting Enzyme 2 and Angiotensin-Converting Enzyme. Journal of the American Society of Nephrology: JASN, 2006, 17, 3067-3075.	6.1	439
95	Antiproteinuric effect of oral paricalcitol in chronic kidney disease. Kidney International, 2005, 68, 2823-2828.	5.2	326
96	Angiotensin II and Renal Tubular Ion Transport. Scientific World Journal, The, 2005, 5, 680-690.	2.1	24
97	Angiotensin II Increases H + -ATPase B1 Subunit Expression in Medullary Collecting Ducts. Hypertension, 2005, 45, 818-823.	2.7	14
98	Guest editorial: Diabetic kidney disease. Advances in Chronic Kidney Disease, 2005, 12, 126-127.	1.4	1
99	Predicting the development of diabetic nephropathy and its progression. Advances in Chronic Kidney Disease, 2005, 12, 202-211.	1.4	12
100	Increased ACE 2 and Decreased ACE Protein in Renal Tubules From Diabetic Mice. Hypertension, 2004, 43, 1120-1125.	2.7	206
101	Nocturnal hypertension: Will control of nighttime blood pressure prevent progression of diabetic renal disease?. Current Hypertension Reports, 2004, 6, 393-399.	3.5	11
102	Clinical and cellular markers of diabetic nephropathy. Kidney International, 2003, 63, 2319-2330.	5.2	25
103	Sodium ferric gluconate complex in hemodialysis patients. II. Adverse reactions in iron dextran-sensitive and dextran-tolerant patients. Kidney International, 2003, 63, 217-224.	5.2	93
104	Paricalcitol versus calcitriol in the treatment of secondary hyperparathyroidism. Kidney International, 2003, 63, 1483-1490.	5.2	331
105	Prevalence, treatment, and control of hypertension in chronic hemodialysis patients in the United States. American Journal of Medicine, 2003, 115, 291-297.	1.5	416
106	Comorbidity and Cardiovascular Risk Factors in Patients With Chronic Kidney Disease. Seminars in Nephrology, 2002, 22, 494-506.	1.6	16
107	Increase in Nocturnal Blood Pressure and Progression to Microalbuminuria in Type 1 Diabetes. New England Journal of Medicine, 2002, 347, 797-805.	27.0	667
108	Circadian changes in blood pressure and their relationships to the development of microalbuminuria in type 1 diabetic patients. Current Diabetes Reports, 2002, 2, 539-544.	4.2	6

#	Article	IF	Citations
109	Na+/H+ exchange activity and NHE-3 expression in renal tubules from the spontaneously hypertensive rat. Kidney International, 2002, 62, 157-165.	5.2	56
110	Hereditary Distal Renal Tubular Acidosis: New Understandings. Annual Review of Medicine, 2001, 52, 471-484.	12.2	69
111	A functional analysis of angiotensin II targets through genome wide surveys. American Journal of Hypertension, 2001, 14, A147-A148.	2.0	0
112	Cultured skin fibroblasts as an in vitro model to assess phenotypic features in subjects with diabetic nephropathy. American Journal of Kidney Diseases, 2001, 38, 646-648.	1.9	12
113	Hypoxia Stimulates Osteopontin Expression and Proliferation of Cultured Vascular Smooth Muscle Cells. Diabetes, 2001, 50, 1482-1490.	0.6	83
114	Osteopontin mediates hypoxia-induced proliferation of cultured mesangial cells: Role of PKC and p38 MAPK. Kidney International, 2000, 58, 691-700.	5.2	52
115	The Application of High Density Microarray for Analysis of Mitogenic Signaling and Cell-Cycle in the Adrenal. Endocrine Research, 2000, 26, 807-823.	1.2	5
116	Temporal profile of serum-induced S-phase entry and retinoblastoma protein phosphorylation in human skin fibroblasts. Kidney International, 1999, 56, 1282-1285.	5.2	7
117	A subdepressor low dose of ramipril lowers urinary protein excretion without increasing plasma potassium. American Journal of Kidney Diseases, 1999, 33, 450-457.	1.9	29
118	Underlying defects in distal renal tubular acidosis: New understandings. American Journal of Kidney Diseases, 1996, 27, 896-915.	1.9	40
119	Growth phenotype of cultured skin fibroblasts from IDDM patients with and without nephropathy and overactivity of the Na+/H+ antiporter. Kidney International, 1996, 50, 1684-1693.	5.2	36
120	Angiotensin II Activation of Cyclin D1-dependent Kinase Activity. Journal of Biological Chemistry, 1996, 271, 22570-22577.	3.4	130
121	Angiotensin II and Angiotensin-(1-7) Effects on Free Cytosolic Sodium, Intracellular pH, and the Na ⁺ -H ⁺ Antiporter in Vascular Smooth Muscle. Hypertension, 1996, 27, 72-78.	2.7	16
122	Renal Tubular Acidosis. Medical Clinics of North America, 1983, 67, 859-878.	2.5	27
123	Distal Renal Tubular Acidosis: Pathogenesis and Classification. American Journal of Kidney Diseases, 1982, 1, 328-344.	1.9	51
124	Distal renal tubular acidosis with intact capacity to lower urinary pH. American Journal of Medicine, 1982, 72, 751-758.	1.5	65
125	Hyperkalemic hyperchloremic metabolic acidosis in sickle cell hemoglobinopathies. American Journal of Medicine, 1982, 72, 188-192.	1.5	97
126	Parathyroid hormone is not anticalciuric during chronic metabolic acidosis. Kidney International, 1982, 22, 264-271.	5.2	24

#	Article	IF	Citations
127	Distal nephron function in patients receiving chronic lithium therapy. Kidney International, 1982, 21, 477-485.	5.2	57
128	Proximal Renal Tubular Acidosis and Hypophosphatemia Induced by Arginine. Advances in Experimental Medicine and Biology, 1982, 151, 239-249.	1.6	4